Last reviewed · How we verify
NCT05481762
Evaluation of Contextflow DETECT Lung CT Nodule Detection Software in Chest CT Scans
trial testing Aided read with contextflow DETECT Lung CT in Lung Cancer in 337 participants. Completed in 30 October 2022.
30 October 2022
Quick facts
| Lead sponsor | contextflow GmbH |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 337 |
| Start date | 1 April 2022 |
| Primary completion | 30 October 2022 |
| Estimated completion | 30 October 2022 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Aided read with contextflow DETECT Lung CT
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
contextflow GmbH
Who can join
22 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
contextflow DETECT Lung CT is a Artificial Intelligence (AI)-based computed-aided detection (CADe) system, intended to support radiologists in the detection of lung nodules in chest computed tomography (CT) scans. System is intended to be used as a second-reader, therefore results provided by the software are meant to complement the radiologist's findings and decisions. Proposed study will be multi-reader, multi case (MRMC) retrospective reader study. The goal of the study is to evaluate the influence of CADe on the effectiveness of lung nodule detection. During the study, 10 radiologists will analyze 350 chest CT scans of adult patients, with and without the assistance of CADe. The study will be conducted remotely. CT scans will be uploaded to a web-based image submission and annotation platform, in which every participant of the study will be provided with individual account and assigned task list. The primary objective of the study determine if the diagnostic accuracy of radiologists with CADe assistance is superior to the diagnostic accuracy of radiologists without CADe assistance in localizing the pulmonary nodules with enhanced area under the free-response operating characteristic curve (AUC of FROC). The study will target approximately 350 asymptomatic adult patients, whose CT scans were acquired during routine CT examination. The patient population will include patients with and without lung nodules.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05481762
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05481762 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by contextflow GmbH
- Last refreshed: 8 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05481762.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing